ranibizumab

ranibizumab. It is a monoclonal antibody fragment designed for intraocular use, specifically targeting and inhibiting vascular endothelial growth factor A. Developed by Genentech, it is marketed under the brand name Lucentis and is primarily administered via intravitreal injection to treat neovascular age-related macular degeneration. Its approval by regulatory bodies like the Food and Drug Administration and the European Medicines Agency represented a significant advancement in retinal therapeutics.

Medical uses

Ranibizumab is indicated for the treatment of neovascular age-related macular degeneration, a leading cause of vision loss in the elderly. It is also approved for managing macular edema following retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. Clinical trials such as ANCHOR, MARINA, and RISE and RIDE demonstrated its efficacy in improving visual acuity and reducing retinal thickness. Treatment typically involves a series of monthly injections, though regimens may be individualized based on patient response as assessed by optical coherence tomography and fluorescein angiography.

Adverse effects

Common adverse events are primarily associated with the injection procedure and include conjunctival hemorrhage, eye pain, and increased intraocular pressure. Serious ocular complications, though rare, can encompass endophthalmitis, retinal detachment, and cataract formation. Systemic risks, such as arterial thromboembolic events, have been observed in clinical studies, though a direct causal relationship remains a subject of ongoing analysis by agencies like the FDA. Patients are typically monitored for signs of ocular inflammation or increased intracranial pressure.

Pharmacology

As a recombinant humanized monoclonal antibody fragment, ranibizumab binds with high affinity to all active isoforms of vascular endothelial growth factor A. This binding inhibits the interaction of VEGF-A with its receptors, VEGFR-1 and VEGFR-2, on the surface of endothelial cells, thereby suppressing angiogenesis and vascular permeability. Its smaller molecular size, compared to full-length antibodies like bevacizumab, is theorized to enhance retinal penetration. The drug is administered locally into the vitreous humour, with systemic exposure being minimal.

History

The development of ranibizumab originated from research into angiogenesis and the role of VEGF in ocular disease at Genentech. It was engineered as a fragment of the parent antibody bevacizumab to optimize ocular pharmacokinetics. Pivotal Phase III clinical trials led to its first approval for neovascular age-related macular degeneration by the FDA in 2006 and by the EMA in 2007. Subsequent approvals expanded its indications, influenced by studies like HARBOR and RESOLVE. Its development history is closely tied to the broader story of anti-VEGF therapies in ophthalmology.

Society and culture

The high cost of ranibizumab has sparked significant debate within healthcare systems worldwide, leading to health technology assessments by bodies like the National Institute for Health and Care Excellence. This economic factor contributed to the widespread off-label use of the significantly less expensive bevacizumab, a practice studied in trials such as CATT and IVAN. The drug is a major revenue generator for Genentech and its commercial partner Novartis. Its impact is frequently discussed in the context of Medicare spending in the United States and drug pricing policies in systems like the National Health Service.

Category:Monoclonal antibodies Category:Ophthalmology